Amphotericin B (AmB) is commonly used in patients with a human immunodeficiency virus (HIV)-positive diagnosis for the treatment of disseminated fungal infections such as Histoplasma spp. or Cryptococcus spp. Newer liposomal formulations of AmB have been introduced to the market to avoid the toxic effects of the traditional agent. With the introduction of these new agents, there is a risk of confusion between the agents in regards to dosing, which may lead to toxicity. We report the case of an HIV-seropositive patient who inadvertently received five times the dose of AmB deoxycholate for disseminated Histoplasma capsulatum and died.
SpanakisE.K., AperisG., MylonakisE.New agents for the treatment of fungal infections: clinical efficacy and gaps in coverage. Clin Infect Dis.2006; 43: 1060–1068.
2.
Centers for Disease Control and Prevention.Treating opportunistic infections among HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association/Infectious Diseases Society of America. MMWR.2004; 53(No. RR-15): 1–115.
3.
MartyF., MylonakisE.Antifungal use in HIV infection. Expert Opin Pharmacother.2002; 3: 91–102.
4.
WheatJ., MaWhinneyS., HafnerR.. Treatment of histoplasmosis with fluconazole in patients with acquired immunodeficiency syndrome. Am J Med.1997; 103: 223–232.
5.
WheatL.J., CloudG., JohnsonP.C.. Clearance of fungal burden during treatment of disseminated histoplasmosis with liposomal amphotericin B versus itraconazole. Antimicrob Agents Chemother.2001; 45: 2354–2357.
6.
JohnsonP.C., WheatL.J., CloudG.A.. Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS. Ann Intern Med.2002; 137: 105–109.
7.
WalshT.J., FinbergR.W., ArndtC.. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med.1999; 340: 764–771.
8.
BowdenR., ChandrasekarP., WhiteM.H.. A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin Infect Dis.2002; 35: 359–366.
9.
MohrJ.F., HallA.C., EricssonC.D., Ostrosky-ZeichnerL.Fatal amphotericin B overdose due to administration of non-lipid formulation instead of lipid formulation. Pharmacotherapy.2005; 25: 426–428.
10.
BurkeD., LalR., FinkelK.W., SamuelsJ., ForingerJ.R.Acute amphotericin B overdose. Ann Pharmacother.2006; 40: 2254–2259.
11.
Institute for Safe Medication Practices.Survey on high-alert medications differences between nursing and pharmacy perspectives revealed. ISMP Medication Safety Alert. October 16, 2003. Available at: http://www.ismp.org/Newsletters/acutecare/articles/20031016.asp. Accessed March 29, 2007.
12.
KorenG., LauA., KenyonC.F., KroppertD., KleinJ.Clinical course and pharmacokinetics following a massive overdose of amphotericin B in a neonate. Clin Toxicol.1990; 28: 371–378.
13.
KoduriP.R., ChundiV., DeMaraisP., MizockB.A., PatelA.R., WeinsteinR.A.Reactive hemophagocytic syndrome: a new presentation of disseminated histoplasmosis in patients with AIDS. Clin Infect Dis.1995; 21: 1463–1465.
14.
RaoR.D., MoriceW.G., PhylikyR.L.Hemophagocytosis in a patient with chronic lymphocytic leukemia and histoplasmosis. Mayo Clin Proc.2002; 77: 287–290.
15.
FismanD.N.Hemophagocytic syndromes and infection. Emerg Infect Dis.2003; 6: 601–608.
